During the corresponding time, Akoya Biosciences Inc saw a revenue deteriorated by -8.68 % year on year, sequentially revenue fell by -29.11 %. While revenue at the Akoya Biosciences Inc 's corporate clients
Akoya Biosciences Inc's Comment on Sales, Marketing and Customers
The company provides products for discovery, translational, and clinical markets, including the PhenoCycler platform for high-plex research and the PhenoImager platforms (Fusion and HT instruments) for translational and clinical applications. The combined PhenoCycler-Fusion system supports spatial discovery at scale. These platforms are used for spatial phenotyping to study diseases such as cancer, neurological and autoimmune disorders, and other therapeutic areas. As of December 31, 2024, the company had 1,330 instruments installed across customers in North America, Asia-Pacific, and Europe-Middle East-Africa regions. The company licenses technology from Stanford and acquired the Phenoptics platform from PerkinElmer, Inc. (now Revvity, Inc.) to expand into translational and clinical markets.
In a remarkable advancement for cancer research and immunotherapy, Akoya Biosciences Inc. has emerged as a pivotal player in the UK-based MANIFEST Consortium, a groundbreaking initiative aimed at revolutionizing how cancer is detected and treated. This consortium, spearheaded by the esteemed Francis Crick Institute and The Royal Marsden NHS Foundation Trust, comprises a coalition of leading universities, hospitals, and industry partners focused on enhancing our understanding of tumor biology through innovative spatial proteomics technologies. The Power of Spatial Proteomics At the heart of the MANIFEST initiative lies the concept of spatial proteomics a cutting-edge approach that allows researchers to examin...
Akoya Biosciences Inc., an industry leader known for the market-leading PhenoImager HT platform and its robust clinical development capabilities, have recently entered into an exclusive agreement with NeraCare. This collaborative synergy is set to revolutionize personalized therapy selection for patients with early-stage melanoma.The partnership brings together Akoya s superior PhenoImager HT platform and clinical development expertise, and NeraCare s cutting-edge Immunoprint test and best-in-class clinical data. The planned result is to significantly enhance access to life-saving therapies for early-stage melanoma patients, thus expanding the frontier of cancer treatment strategies and opening new horizons ...
In a groundbreaking development, Akoya Biosciences Inc. has successfully deployed the MaxFuse algorithm, co-developed by Dr. Garry Nolan and his laboratory at Stanford University. This algorithm enables the integration of datasets from various biomedical modalities, including spatial proteomics, spatial transcriptomics, single-cell sequencing, and more. Referred to as the Enable Medicine Platform, this innovative technology opens up new possibilities for researchers and scientists to gain deeper insights into the complex world of multiomic integration.The MaxFuse algorithm is a game-changer in the field of biomedical research. By facilitating the matching and integration of diverse datasets, it enhances the ...
Akoya Biosciences Inc’s Comment on Sales, Marketing and Customers
The company provides products for discovery, translational, and clinical markets, including the PhenoCycler platform for high-plex research and the PhenoImager platforms (Fusion and HT instruments) for translational and clinical applications. The combined PhenoCycler-Fusion system supports spatial discovery at scale. These platforms are used for spatial phenotyping to study diseases such as cancer, neurological and autoimmune disorders, and other therapeutic areas. As of December 31, 2024, the company had 1,330 instruments installed across customers in North America, Asia-Pacific, and Europe-Middle East-Africa regions. The company licenses technology from Stanford and acquired the Phenoptics platform from PerkinElmer, Inc. (now Revvity, Inc.) to expand into translational and clinical markets.
Sources:
Akoya Biosciences Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Akoya Biosciences Inc’s corporate clients.
For your research, we’ve provided 9 tables on Akoya Biosciences Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
104.84 %